Treatment of overweight/obese type 2 diabetic patients with the long-acting FGF21 analogue (PF-05231023) significantly reduced circulating triglyceride and low-density sterol levels and increased high-density lipoprotein and adiponectin levels (101). This evidence concerns the gene FGF21 and type 2 diabetes mellitus.